PTC Therapeutics
PTCT | NASDAQ
$60.97
-$2.52 (-3.97%)
At close: Nov 16, 2026, 4:00 PM ET
$59.70
-$1.27 (-2.08%)
After-hours:
Nov 16, 2026, 7:31 PM ET
PTC Therapeutics Company Profile
Company profile explainedCompany Profile
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Matthew Klein | Chief Executive Officer & Director |
| Linda Montella Carter | Senior Vice President & Chief Information Officer |
| Mark Elliott Boulding | Executive Vice President & Chief Legal Officer |
| Pierre Gravier | Chief Financial Officer |
| Allan Steven Jacobson | Co-Founder & Independent Director |
| Christine Utter | Senior Vice President, Chief Accounting Officer & Head of People Services |
| Ellen Cavaleri | Head of Investor Relations |
| Eric Pauwels | Chief Business Officer |
| Lee Golden | Executive Vice President & Chief Medical Officer |
| Neil Almstead | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 16, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 09, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
PTC Therapeutics
| Country | United States |
| IPO Date | Jun 20, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 991 |
| CEO | Matthew Klein |
Contact Details
500 Warren Corporate Center Drive Warren,
New Jersey 07059 United States
Stock Details
| Ticker Symbol | PTCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070081 |
| CUSIP Number | 69366J200 |
| ISIN Number | US69366J2006 |
| SIC Code | 2834 |
Recent News
- 18 days ago / seekingalpha.comPTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
- 18 days ago / zacks.comPTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 18 days ago / zacks.comPTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
- 26 days ago / zacks.comAnalysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
- 2 months ago / seekingalpha.comPTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 3 months ago / seekingalpha.comPTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
- 3 months ago / zacks.comPTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- 4 months ago / zacks.comPTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- 4 months ago / seekingalpha.comPTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
- 4 months ago / zacks.comPTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
Add to Watchlist
Select watchlists to add or remove PTCT